Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.
Also called NCT03994471
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 170 participants
- Sponsor
- Iperboreal Pharma Srl
- Registry
-
NCT03994471 -
2019-004183-21
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark, Germany, Italy, Spain, Sweden, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT03994471. Randomized; single masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
- Acronym
- ELIXIR
- Condition
- End Stage Renal Disease
- Intervention (Drug)
- XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
- Intervention (Drug)
- 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
- Lead sponsor
- Iperboreal Pharma Srl
Record details
- Record id
cardio:ct-nct03994471- Content hash
060de8b1f6c976c28d86700c5c163c3ad958a3a6ff48829d0f03aea8b8937e4a